Isentress Durability for Drug-Naïve HIV patients - 0 views
-
Christine Redmond on 09 Dec 09Isentress is a new HIV treatment in development. Recent studies have shown Isentress-based therapy maintains activity at 96 weeks in treatment-naïve HIV patients, comparable to efavirenz, which is a current favourite for this patient pool. The benefits of Isentress-based therapy, however, are improved side effect and lipid profiles.